ISSN
1916-6958

2010;
Volume 1 (Number 1): Pages 1-2

EDITORIAL

Good news: the Journal of
Theoretical and Experimental Pharmacology was born

Alejandro A.
NAVA-OCAMPOa,b

aDepartment of
Pharmacology & Toxicology, Faculty of Medicine, University of Toronto,
Toronto, Canada

bPharmaReasons, Toronto, Canada

Correspondence:
[email-masked]

The story on how this journal was planned is full of
anecdotes, friendship, and passion for work. However, I am sure that none of
members of the small group of colleagues who conceived the original idea of the
journal realized all the difficulties that would need to be sorted out to see
the first issue of the journal published.

The Journal of Theoretical and Experimental
Pharmacology welcomes any pharmacological research performed in silico, in
vitro, and in experimental animal models including computer simulations
with potential pharmacological interest; SAR and QSAR analyses; dose-response
evaluations; drug-drug interactions; drug effects at cellular and sub-cellular
levels; in vitro and in vivo metabolic studies; and
pharmacokinetic, pharmacodynamic, and teratogenic studies. The journal is
also accepting for consideration for publication studies in the field of
pharmacogenetics, pharmacogenomics, and preclinical toxicology.

Studies evaluating the effects of vitamins, hormones,
immunological mediators, or chemicals are also welcomed if any of the topics
mentioned above are the focus of the study. At this time, only invited review
articles are being accepted. However, systematic reviews and meta-analysis of
preclinical pharmacological studies are also welcomed through the standard
submission process.

The journal will also consider for publication
manuscripts devoted to the analysis of philosophical and ethical aspects of
biomedical sciences. These latter topics are intended to enrich the content of
the journal and to make it an open space where ethical and philosophical
dilemmas can be analyzed and debated.

I am excited by the response of colleagues from around
the world to my invitation to join us in this adventure. Currently, 24 scientists
from 13 different countries around the world are members of the Editorial
Board. In this very first issue the journal publishes two review papers and two
original studies. All of them are of such a high quality that I should thank
the authors, including my Mexican colleagues, for considering this journal as
their option for publishing these papers instead of preferring well-established
journals.

SERAFIM et al. [1] reviewed the
potential role of several phenolic acids and derivatives as anti-cancer agents,
highlighting the role of mitochondria as a primary subcellular target for this
class of compounds. Plant-derived phenolic compounds are widely consumed in a
normal diet, especially in fruits and vegetables. Interestingly, phenolic acids
have been reported to display antiproliferative activity by promoting selective
induction of tumor cell apoptosis and by triggering the mitochondrial pathway
for apoptosis. CANAPARO & SERPE [2] reviewed single
nucleotide polymorphisms as a source of human genetic and phenotypic variation
and their contribution to the variability of drug action. However, as the
authors duly noted, any time genetics plays a role modifying drug effects,
there likely is a complex interplay of several genes rather than the action of
a single one.

GONZÁLEZ-LOZANO et al. [3] evaluated the
obstetric and fetal outcomes in dystocic sows receiving udder massage
stimulation alone or in combination with oxytocin. The authors observed that dystocic
sows receiving udder massage had better obstetric and fetal outcomes than
control sows. However, co-administration of oxytocin might reverse the
advantages of udder massage. Finally, KIM et al. [4] examined the
molecular mechanism of how Histone deacetylase (HDAC) inhibitors modulate the
cell cycle regulators and tumor suppressor genes in prostate cancer cells. The
study found that HDAC inhibitors may prevent the proliferation of prostate
cancer cells by altering the expression of the cell cycle regulators and tumor
suppressor genes, which might be associated with epigenetic regulation.

The journal is published electronically in the English
language only. However, the abstracts are available in three different
languages. Translation of the abstracts to French and Spanish was made possible
by colleagues who volunteered for this task.

This issue was supported by submission fees for
original papers as well as by generous support from PharmaReasons, Toronto, Canada.
However, the final acceptance of the manuscripts was independent of the
journal’s supporter. All the manuscripts can be downloaded at no cost.

As Editor, I express gratitude to my friends and
colleagues who have worked alongside me since the beginning of this project.
The authors and the readers of this journal deserve a special note of gratitude
for trusting us.

REFERENCES

[1]      Serafim TL, Marques MP, Borges FM, Oliveira PJ. Mitochondria
as a target for novel chemotherapeutics agents based on phenolic acids. J Theor
Exp Pharmacol 2010; 1: 3-13.

[2]      Canaparo R, Serpe L. Beyond single nucleotide
polymorphisms. J Theor Exp Pharmacol 2010; 1: 14-20.

[3]      González-Lozano M, Mota-Rojas D, Nava-Ocampo
AA, Alonso-Spilsbury M, Velázquez-Armenta EY, Ramírez-Necoechea
R, et al. Perinatal outcomes to uterine stimulation with breast
massage alone or in combination with oxytocin in dystocic sows. J Theor Exp Pharmacol
2010; 1: 21-26.

[4]      Kim HJ, Choi WS, Lee J, HAN JY, Kim HS. Differential
effects of histone deacetylase inhibitors on cell cycle regulation and apoptosis
in human prostate cancer cells. J Theor Exp Pharmacol 2010; 1: 27-36.

www.premiumreasons.com/JTEP/JTEP.html

© PremiumReasons